Barrett P A, Jordan J L, Mandel W J, Yamaguchi I, Laks M M
Am Heart J. 1979 Aug;98(2):213-24. doi: 10.1016/0002-8703(79)90224-2.
Fourteen patients with the Wolff-Parkinson-White (WPW) syndrome were studied by means of intracardiac stimulation techniques, before and after the intravenous administration of propranolol, 0.1 mg./Kg. There were no significant change, or only a slight increase, in the effective refractory periods of all parts of the re-entry tachycardia circuit studied, in either anterograde or retrograde directions. Re-entry tachycardia was initiated in nine patients in the control state, and in 10 patients after propranolol. The rate of re-entry atrioventricular node-accessory pathway tachycardia was decreased, but by only 10 per cent. The duration and outer limit of the tachycardia zone of atrial extrastimuli were not significantly decreased. Propranolol, by rapid intravenous infusion administration, is unlikely to be effective primary therapy for PSVT in the WPW syndrome.
对14例预激综合征(WPW)患者在静脉注射0.1mg/kg普萘洛尔前后,采用心内刺激技术进行了研究。在所研究的折返性心动过速环路各部分的有效不应期,无论是顺行还是逆行方向,均无显著变化,或仅有轻微增加。在对照状态下,9例患者诱发了折返性心动过速,在使用普萘洛尔后,10例患者诱发了折返性心动过速。房室结-附加旁路折返性心动过速的折返率降低,但仅降低了10%。房性期外刺激心动过速区的持续时间和外缘无显著缩短。通过快速静脉输注给药,普萘洛尔不太可能成为WPW综合征中阵发性室上性心动过速(PSVT)的有效初始治疗方法。